CSIMarket
 


Medicines Co  (MDCO)
Other Ticker:  
 

Cumulative Medicines Co's Working Capital Ratio for Trailing Twelve Months Period

MDCO's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

MDCO Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
(Mar 31 2019)
I. Quarter
(Dec 31 2018)
IV. Quarter
(Sep 30 2018)
III. Quarter
Y / Y Current Liabilities Growth 444.18 % -24.23 % -42.83 % -66.72 % -39.68 %
Y / Y Current Assets Growth 74.49 % 74.22 % -8.83 % -47.67 % -37.13 %
Working Capital Ratio for Trailing Twelve Months Period 2.07 4.26 3.38 2.97 2.8
Total Ranking # 1886 # 921 # 1183 # 1360 # 1374
Seq. Current Liabilities Growth 561.53 % 1.3 % 8.1 % -24.88 % -7.89 %
Seq. Current Assets Growth -14.39 % 47.86 % -12.45 % 57.44 % -14.52 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2019
On the trailing twelve months basis Due to doubling in Current Liabilities in the III. Quarter to $423 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 2.07 below Medicines Co average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 418 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Medicines Co. While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about MDCO
Working Capital Ratio MDCO in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 419
Sector # 799
S&P 500 # 3875


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
4.26 2.53 1.37
(Jun 30 2019)   (Sep 30 2017)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2019, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Dynavax Technologies Corporation  5.69 
Intercept Pharmaceuticals inc   5.66 
Immuron Limited  5.59 
Clovis Oncology inc   5.59 
Tetraphase Pharmaceuticals Inc  5.50 
Alpine Immune Sciences Inc   5.49 
Travere Therapeutics Inc   5.48 
Oncosec Medical Incorporated  5.44 
Pds Biotechnology Corp  5.42 
Ampio Pharmaceuticals inc   5.40 
Stemline Therapeutics Inc  5.31 
Redhill Biopharma Ltd   5.24 
Portola Pharmaceuticals inc   5.23 
Macrogenics Inc   5.20 
Scynexis Inc   5.17 
Syndax Pharmaceuticals Inc   5.16 
Ligand Pharmaceuticals Incorporated  5.14 
Mersana Therapeutics Inc   5.12 
Verastem inc   5.09 
Phio Pharmaceuticals Corp   5.07 
Xoma Corporation  5.06 
Merrimack Pharmaceuticals Inc  5.05 
Salarius Pharmaceuticals inc   5.05 
Fibrocell Science, Inc.  5.05 
Bioxcel Therapeutics Inc   5.04 
Lexicon Pharmaceuticals Inc   4.97 
Ovid Therapeutics Inc   4.97 
Chiasma Inc   4.96 
Tyme Technologies Inc.  4.93 
Theriva Biologics inc   4.93 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com